Collection of Blood and Urine From Patients Undergoing Radiation Therapy
Launched by NATIONAL CANCER INSTITUTE (NCI) · Nov 30, 2001
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
BACKGROUND:
Evolving research initiatives in the Radiation Oncology Branch (ROB) NCI, depend upon the availability of blood and urine samples from patients receiving radiotherapy.
Examples of planned studies include an exploration of the effects of radiotherapy on peripheral leukocyte phenotype, peripheral blood protein and metabolism changes as well as measurements of matrix metalloproteinases (MMP) in urine.
OBJECTIVES:
This protocol provides a means of acquiring blood and urine samples in patients receiving radiation therapy for a variety of conditions.
ELIGIBILITY:
Patients seen i...
Gender
ALL
Eligibility criteria
- * INCLUSION CRITERIA:
- • 1. Patients must be co-enrolled in a NIH CC protocol in which radiation will be administered.
- • 2. Patients must a candidate for, or currently receiving radiotherapy.
- • 3. Age greater than or equal to 18 years.
- • 4. Ability of subject or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document.
- EXCLUSION CRITERIA:
- • 1. Patients who have unobtainable data regarding previous radiation therapy.
About National Cancer Institute (Nci)
The National Cancer Institute (NCI) is a prominent component of the National Institutes of Health (NIH), dedicated to advancing cancer research and improving patient outcomes through innovative clinical trials. As a leading sponsor of cancer-related studies, NCI focuses on facilitating the development of new therapies, enhancing prevention strategies, and understanding the biology of cancer. The institute collaborates with academic institutions, healthcare providers, and industry partners to conduct rigorous clinical trials that aim to translate scientific discoveries into effective treatments. NCI’s commitment to fostering a robust research environment supports the mission to eliminate cancer as a major health problem.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bethesda, Maryland, United States
Bethesda, Maryland, United States
Patients applied
Trial Officials
Kevin A Camphausen, M.D.
Principal Investigator
National Cancer Institute (NCI)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials